Status:
RECRUITING
Pulmonary Epithelium, Immunology and Development of Asthma: Breathing Together
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
Queen Mary University of London
University of Bristol
Conditions:
Asthma
Wheezing
Eligibility:
All Genders
5-16 years
Brief Summary
The investigators want to know why some babies wheeze and some of these go on to develop asthma. The investigators are going to find out if babies who develop wheeze and asthma have abnormal airway li...
Detailed Description
The cells that line the airways act as a barrier to infections and proteins that cause allergy, and also release a host of signalling molecules. It known that these airway cells in children with estab...
Eligibility Criteria
Inclusion
- expectant mother or infant aged 0-10 days
- children with recurrent wheezing and other clinical atopy
- children with recurrent wheezing and no obvious wheezing triggered by aeroallergens and no clinical evidence of other atopy.
- children with no history of wheezing but with at least one clinically apparent atopic disorder
- children with no history of wheezing and with no clinical evidence of other atopic disorder
- all children will be undergoing an elective surgical procedure
- all children will have been born at term (37-42 weeks gestation)
- the anaesthetist will have deemed the child fit for elective surgery, free from a recent respiratory tract infection, stable and suitable for the research study samples to be taken.
- in the case of blind non-bronchoscopic sample suitable for endotracheal intubation or for a fibre-optic bronchoscopy if this is the chosen method of sampling
Exclusion
- pre-term infants (\<37 weeks gestation)
- twins or other multiples
- maternal group B streptococcus on high vaginal swab in the present pregnancy
- need for CPAP or ventilatory support in the neonatal period
- infants with major concurrent health problems, e.g. congenital heart disease, cystic fibrosis, those requiring special feeding regimens on account of prematurity or illness
- infants who will not be available to assess acutely if they develop wheeze
- infants who are likely to move away from the study centre before 3 years of age
- children with a recent respiratory tract illness (should have recovered \> 2 weeks)
- children with other major respiratory illnesses such as and including Cystic Fibrosis, Chronic Neonatal Lung Disease, pulmonary aspiration syndromes.
- children with evidence of a systemic inflammatory or infective condition
- children with a history of previous pituitary or ethmoid surgery
Key Trial Info
Start Date :
February 20 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 18 2024
Estimated Enrollment :
1300 Patients enrolled
Trial Details
Trial ID
NCT04063631
Start Date
February 20 2017
End Date
September 18 2024
Last Update
January 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Brompton and Harefield NHS Foundation Trust
London, United Kingdom, SW£ 6NP